Neuroendocrine Brake for Type 2 Diabetes Mellitus

August 21, 2014 updated by: Medtronic - MITG

Phase IV Study of Neuroendocrine Brake Surgical Procedure for Type 2 Diabetes Mellitus

Evaluation to determine the safety of two laparoscopic procedures to control T2DM.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment

40

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Goiania, Brazil
        • Hospital de Especialidades

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. - Male and female between 18 and 65 years.
  2. BMI 25.1 - 34.9.
  3. Type 2 diabetic patients on oral anti-diabetic agents and/or insulin treatment for a minimum of 12 months prior the enrollment.
  4. Diagnosis of T2DM for at least 3 years.
  5. Patient has been under routine care of hte study physician or another physician that can supply a reliable medical record for at least 3 years.
  6. HbA1c >/ 7.5 documented for at least 3 months.
  7. Stable weight (nor significant weight change (>3%) over the 3 months prior to enrollment.
  8. Stable medication for at least one month prior to enrollment except for diabetes medications which should be stable for at least 3 months prior to enrollment.
  9. Ability and willingness to return for all scheduled visits and participate in recommended parameter setting and physician recommended medical/laboratory assessments.

Exclusion Criteria:

  1. Prior abdominal surgery, except laparoscopic cholecystectomy.
  2. Taking appetite suppressant.
  3. Severe eating disorders.
  4. Severe pulmonary, renal or cardiac disease.
  5. Obese due to a clinically diagnosed endocrine disorder.
  6. Subjects with impaired liver function.
  7. History of peptic ulcer disease.
  8. History of malignant disease.
  9. Use of prescription, over the counter or herbal weight loss products.
  10. Pregnant or planning on pregnancy while enrolled in study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.

Secondary Outcome Measures

Outcome Measure
Evaluate neurohormonal effect in treating T2DM.
Improvement or control of blood glucose levels.
Improvement or control of comorbidities associated with T2DM.
Hormonal effect and effect of the operations on diabetes related and total mortality.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Noreen A Gannon, Medtronic - MITG
  • Principal Investigator: Aureo DePaula, MD, Hospital de Especialidades

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2006

Primary Completion (Actual)

September 1, 2008

Study Completion (Actual)

September 1, 2009

Study Registration Dates

First Submitted

March 21, 2007

First Submitted That Met QC Criteria

March 21, 2007

First Posted (Estimate)

March 22, 2007

Study Record Updates

Last Update Posted (Estimate)

August 22, 2014

Last Update Submitted That Met QC Criteria

August 21, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

Clinical Trials on ileal interposition with a sleeve gastrectomy

3
Subscribe